Tevogen Bio Holdings (TVGN)
NASDAQ:TVGN
Want to see TVGN full AI Analyst Report?
Top Page
Tevogen Bio Holdings
(NASDAQ:TVGN)
Select Model
Select Model
Rating:50Neutral
Price Target:
$11.50
▲(3493.75% Upside)
Action:Reiterated
Date:06/07/26
The score is held down primarily by weak financial performance (no revenue, sustained losses and cash burn, and negative equity). Technical momentum is currently supportive, but valuation remains unfavorable due to unprofitability, and Nasdaq market-value compliance risk is an added overhang.
Positive Factors
T‑cell immunotherapy platform
Tevogen's focus on precision CTL (T‑cell) therapies for infectious disease and cancer represents a durable, proprietary therapeutic approach. Platform-driven cell therapies can yield high barriers to entry, repeatable R&D pathways, and licensing or partnership optionality that support long-term value creation if clinical proof points are achieved.
Negative Factors
No revenue, persistent losses
The absence of revenue and ongoing operating losses create chronic funding dependency and dilution risk. Sustained negative profitability and cash burn (roughly $12M TTM) mean the company must access external capital to advance trials, limiting self‑funding capacity and making progress contingent on market financing conditions.
Read all positive and negative factors
Positive Factors
Negative Factors
T‑cell immunotherapy platform
Tevogen's focus on precision CTL (T‑cell) therapies for infectious disease and cancer represents a durable, proprietary therapeutic approach. Platform-driven cell therapies can yield high barriers to entry, repeatable R&D pathways, and licensing or partnership optionality that support long-term value creation if clinical proof points are achieved.
Read all positive factors
Tevogen Bio Holdings (TVGN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$39.91M
Dividend YieldN/A
Average Volume (3M)557.82K
Price to Earnings (P/E)―
Beta (1Y)1.12
Revenue GrowthN/A
EPS Growth38.95%
CountryUS
Employees18
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.84
Shares Outstanding4,219,343
10 Day Avg. Volume531,944
30 Day Avg. Volume557,817
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-6.68
Price to Sales (P/S)0.00
P/FCF Ratio-4.44
Enterprise Value/Market Cap1.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-299.01
Enterprise Value/Ebitda-2.08
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-10.14
Revenue Forecast (FY)N/A
Tevogen Bio Holdings Business Overview & Revenue Model
Company Description
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precisio...
How the Company Makes Money
null...
Tevogen Bio Holdings Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
14
Very Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -144.84K | 0.00 | -403.58K | -378.36K | 0.00 | 0.00 |
| EBITDA | -20.83M | -25.57M | -13.14M | -58.89M | 4.64M | -14.99M |
| Net Income | -21.35M | -26.28M | -10.11M | -60.48M | 4.41M | -15.60M |
Balance Sheet | ||||||
| Total Assets | 4.92M | 4.38M | 3.46M | 5.51M | 7.74M | 7.66M |
| Cash, Cash Equivalents and Short-Term Investments | 692.30K | 552.37K | 1.28M | 1.05M | 5.48M | 7.12M |
| Total Debt | 3.07M | 3.10M | 2.89M | 95.42M | 40.01M | 23.48M |
| Total Liabilities | 14.76M | 12.62M | 10.14M | 99.93M | 41.69M | 24.15M |
| Stockholders Equity | -9.84M | -8.23M | -6.67M | -94.43M | -33.95M | -16.49M |
Cash Flow | ||||||
| Free Cash Flow | -11.82M | -12.39M | -12.00M | -8.30M | -9.13M | -5.38M |
| Operating Cash Flow | -11.75M | -12.33M | -12.00M | -8.17M | -8.66M | -5.27M |
| Investing Cash Flow | -64.44K | -64.44K | 0.00 | -133.00K | -479.04K | -109.73K |
| Financing Cash Flow | 10.54M | 11.66M | 12.23M | 3.87M | 7.50M | 12.50M |
Tevogen Bio Holdings Technical Analysis
Neutral
0.32
Price Trends
8.25
Positive
9.07
Positive
18.42
Negative
Market Momentum
0.49
Positive
50.76
Neutral
13.91
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TVGN, the sentiment is Neutral. The current price of 0.32 is below the 20-day moving average (MA) of 9.61, below the 50-day MA of 8.25, and below the 200-day MA of 18.42, indicating a neutral trend. The MACD of 0.49 indicates Positive momentum. The RSI at 50.76 is Neutral, neither overbought nor oversold. The STOCH value of 13.91 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TVGN.
Tevogen Bio Holdings Risk Analysis
Tevogen Bio Holdings disclosed 76 risk factors in its most recent earnings report. Tevogen Bio Holdings reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tevogen Bio Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $458.85M | -5.04 | -50.68% | ― | -12.37% | 19.59% | |
54 Neutral | $366.58M | -11.91 | -147.78% | ― | ― | -16.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $39.91M | -1.54 | 241.39% | ― | ― | 38.95% | |
45 Neutral | $204.62M | -2.13 | -30.90% | ― | ― | 10.70% | |
45 Neutral | $447.34M | -11.14 | -60.73% | ― | -78.29% | 54.16% |
* Healthcare Sector Average
TVGN
Tevogen Bio Holdings
9.46
-48.54
-83.69%
NKTX
Nkarta
2.86
1.12
64.37%
CCCC
C4 Therapeutics
4.15
2.68
182.31%
STTK
Shattuck Labs
4.95
3.94
390.10%
NVCT
Nuvectis Pharma
13.82
5.86
73.62%
ACTU
Actuate Therapeutics, Inc.
2.07
-4.98
-70.64%
Tevogen Bio Holdings Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
Tevogen Bio Faces Nasdaq Market Value Compliance Challenges
Negative
Apr 22, 2026
On April 16, 2026, Tevogen Bio Holdings Inc. was notified by Nasdaq that it no longer meets the $50 million minimum market value of listed securities required for continued listing on the Nasdaq Global Market, based on the prior 30 consecutive bus...
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
Tevogen Bio Regains Nasdaq Compliance After Reverse Split
Positive
Mar 25, 2026
Tevogen Bio Holdings Inc. announced that on March 20, 2026, it received notice from Nasdaq that the company had regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market, resolving a prior listing...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.